Animal Models Core

Document text

Principal Investigator: MYRON E HINSDALE
Organization: OKLAHOMA STATE UNIVERSITY STILLWATER
Fiscal Year: 2024
Award: $191,154
Funding agency: National Institute of General Medical Sciences

Animal Models Core
Project Summary:
Centers of Biomedical Research Excellence Phase I and II funding for the animal models core (AMC)
established a research core with expertise in respiratory and infectious diseases, including state-of-the-art
equipment and animal biosafety level 2 (ABSL-2) housing and procedural facilities. With Phase III the AMC will
be expanding its services for the ABSL-2 studies with new cutting-edge equipment for phenotyping of animal
models of respiratory and infectious disease. In addition, the AMC will be expanding its services to ABSL-3
animal models to better address the urgent needs for BSL3 research at the state level as well as the national
level. The central objective of this Phase III proposal is to strengthen the existing BSL2 infrastructure and
services and enhance the AMC with ABSL-3 capabilities to adapt to the expanding needs in respiratory and
infectious disease research in Oklahoma. The aims of this proposal are: i) Aim 1: Provide a state-of-the-art
ABSL-2/3 service to CoBRE pilot projects and other Oklahoma researchers; ii) Aim 2: Provide ABSL-2/3
experimental and regulatory training to CoBRE investigators; iii) Aim 3: Develop a sustainable and
independent ABSL-2/3 AMC for use beyond Phase III funding. As a result of Phase III activities, the AMC
will increase interdisciplinary interactions between and training of Oklahoma Center for Respiratory Infectious
Disease (OCRID) researchers at Oklahoma State University, University of Oklahoma and Oklahoma Medical
Research Foundation.

Terms: <2019-nCoV vaccine><Address><Animal Experiments><Animal Model><Animal Models and Related Studies><Animal Welfare><Animals><Anti-viral Agents><Applications Grants><BSL-3 facility><BSL3 facility><Breeding><COBRE><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 years><Center of Biomedical Research Excellence><Centers of Research Excellence><Clinical Evaluation><Clinical Testing><Collaborations><Communicable Diseases><Communities><Contracting Opportunities><Contracts><Coronaviridae><Coronavirus><Discipline><Documentation><EXTMR><Ensure><Equipment><Extramural><Extramural Activities><Faculty><Fee-for-Service Plans><Fees for Service><Fostering><Foundations><Funding><Genotype><Goals><Grant Proposals><Hand functions><Housing><IACUC><Immunology><Industry><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Infrastructure><Institution><Institutional Animal Care and Use Committee><Instruction><Investigators><Knock-in><Knock-out><Knockout><Letters><M tb><M tuberculosis><M. tb><M. tuberculosis><Medical Research><Mission><Modeling><Mycobacterium tuberculosis><Oklahoma><Phase><Phenotype><Pilot Projects><Productivity><Protocol><Protocols documentation><Qualifying><R-Series Research Projects><R01 Mechanism><R01 Program><Regulation><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Researchers><Respiratory Center><Respiratory Disease><Respiratory Function Tests><Respiratory System Disease><Respiratory System Disorder><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><Schedule><Services><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Technology><Training><Transgenic Animals><Universities><Using hands><Vaccines><Viral><Viral Pathogenesis><Work><animal experiment><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><base><bases><biosafety level 3 facility><clinical test><corona virus><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><emerging pathogen><experimental animal><experimental animals><industrial partnership><industry partner><industry partnership><infectious disease model><interdisciplinary collaboration><knockin><member><model of animal><mtb><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><new pathogen><novel pathogen><pathogen><pilot study><pre-clinical><preclinical><programs><prospective><research clinical testing><respiratory><respiratory pathogen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><success><transdisciplinary collaboration><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><virology><virus pathogenesis>